Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointment of Michael Halstead as chief executive officer, effective immediately. The move comes at a pivotal time as the clinical-stage company advances its lead candidate HLP003 through Phase 3 development and readies for potential commercialization. Halstead brings over 25 years of biopharmaceutical leadership experience, having most recently served as president of Intra-Cellular Therapies, where he oversaw the development and commercialization of CAPLYTA, supported pipeline expansion, and helped lead the company’s $14.6 billion acquisition by Johnson & Johnson in 2025.
The announcement arrives as Helus Pharma reports enrollment completion in the Phase 3 APPROACH trial, with topline data expected in Q4 2026. Additionally, enrollment continues in the EMBRACE pivotal study, while the company also advances HLP004 for generalized anxiety disorder. This leadership transition is strategically timed to align with key clinical milestones and the company’s broader goal of bringing novel mental health treatments to market.
Halstead’s appointment is seen as a significant step for Helus Pharma, which is focused on developing proprietary serotonergic agonists (NSAs) designed to promote neuroplasticity and address unmet needs in depression and anxiety. The company’s lead candidate, HLP003, is a proprietary NSA in Phase 3 for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
With a robust research portfolio, Helus Pharma aims to improve the treatment landscape by introducing therapies that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The appointment of a seasoned executive like Halstead underscores Helus Pharma’s commitment to advancing its pipeline and preparing for the commercial stage. As the company approaches critical data readouts, its leadership team is positioning itself to navigate the complexities of regulatory approval and market entry. The implications of this announcement are significant: it signals confidence in the company’s clinical programs and its ability to execute on strategic priorities.
Investors and industry observers will be watching closely as Helus Pharma progresses toward its Phase 3 milestones. The company’s recent newsroom updates can be found at https://nnw.fm/HELP. With a clear focus on innovation and a strengthened leadership team, Helus Pharma is well-positioned to make a meaningful impact in mental health care.
